` BCEL (Atreca Inc) vs S&P 500 Comparison - Alpha Spread

A
BCEL
vs
S&P 500

Over the past 12 months, BCEL has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Stocks Performance
BCEL vs S&P 500

Loading
BCEL
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BCEL vs S&P 500

Loading
BCEL
S&P 500
Difference
www.alphaspread.com

Performance By Year
BCEL vs S&P 500

Loading
BCEL
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Atreca Inc vs Peers

S&P 500
BCEL
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Atreca Inc
Glance View

Market Cap
3.6m USD
Industry
Biotechnology

Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.

BCEL Intrinsic Value
Not Available
A
Back to Top